SI-Bone price target lowered to $20 from $24 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on SI-Bone (SIBN) to $20 from $24 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that a premium multiple is justifiable for the stock given the company’s faster top-line growth profile relative to its peers, combined with above-average gross margin and improving profitability outlook.